You are currently viewing the summary.
View Full TextAs a service to the community this article is available to view for free. Use your via AAAS ID to log in or register for a free account
This article has a correction. Please see:
Summary
The biotechnology company Celera has generated controversy by reporting that it will sequence the human genome in 3 years with the aid of 230 new high-throughput DNA sequencing machines, well before the efforts of the Human Genome Project are slated to be competed. Now J. C. Mullikin and A. A. McMurray report their evaluation of this sequencer, the ABI 3700 from Perkin-Elmer.
